Purpose: the leading cause of mortality in military trauma is from uncontrolled haemorrhage, with the mainstay of treatment for resuscitation of haemorrhagic shock previously being administration of blood products only. Tranexamic acid (TXA) is a drug that acts by binding plasminogen and blocking its conversion to plasmin, thus reducing fibrinolysis and stopping dissolution of the blood clot. TXA is an inexpensive and effective treatment that has been shown to reduce bleeding and mortality. Given that military personnel are a subset of the population at enhanced risk of severe injury and venous thromboembolism (VTE) some concerns remain regarding the potential rate of VTE following its administration. Method: A review of literature was performed to provide a summary of current evidence existing for use of tranexamic acid in military application of reducing haemorrhage, its survival benefits, and risk of VTE. Search terms included “tranexamic acid, military, combat, trauma, bleeding, venous thromboembolism”. Results: use of TXA in conjunction with blood-component based resuscitation following combat injury results in improved survival, particularly in patients requiring massive transfusion (MT). The evidence regarding rates of VTE following administration of MT resuscitation and TXA in military combat patients is mixed. Conclusion: TXA reduces overall mortality from haemorrhage when administered alongside blood products in patients requiring MT. The general consensus remains that patients should be monitored for clinical signs of VTE following administration of TXA.